Rydapt is a twice daily oral FLT3 inhibitor for the treatment of newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Rydapt is also FDA approved for treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia.

If you have a Hayes login, click here to view the full report on the Knowledge Center.